why choose us

300×250 Ad Slot

Research Article: Anti-CD137 agonist antibody–independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma

Date Published: 2025-03-12

Abstract:
Background: Tumor infiltrating lymphocytes (TILs) therapy has been proved for treatment of metastatic melanoma and is under investigation for other types of solid tumors. However, these successes are threatened by discontinued supply of GMP-grade anti-CD137 agonist, a key TIL preparation reagent. Therefore, exploring a GMP-adherent method for expanding endogenous TILs without anti-CD137 agonist is urgent. Toward this end, we aimed to establish an anti-CD137–independent and clinically feasible TIL expansion protocol to prepare TILs from under investigated sarcoma tumors.

No summary available.

300×250 Ad Slot